The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen The post FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine appeared first on Pharmaceutical Business review. … [Read more...]
How Data Shapes the Future of Omnichannel Marketing
Vanda partners with OliPass to develop ASO-based therapeutics
The collaboration will use the companies’ respective strengths to support the development of ASO-based precision medicine therapies and for creating compelling value opportunities for Vanda and OliPass. It The post Vanda partners with OliPass to develop ASO-based therapeutics appeared first on Pharmaceutical Business review. … [Read more...]
Verismo Therapeutics Snags Orphan Drug Designation
Phase 1 clinical trials evaluating the drug will begin in the first quarter of 2023. … [Read more...]
US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis
This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human The post US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis appeared first on Pharmaceutical Business review. … [Read more...]